Please use this identifier to cite or link to this item: doi:10.22028/D291-37725
Volltext verfügbar? / Dokumentlieferung
Title: Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC
Author(s): Aldhaam, Naif A.
Elsayed, Ahmed S.
Jing, Zhe
Richstone, Lee
Wagner, Andrew A.
Rha, Koon Ho
Yuh, Bertram
Palou, Juan
Khan, Muhammad Shamim
Menon, Mani
Roupret, Morgan
Balbay, Derya
Hosseini, Abolfazl
Wiklund, Peter
Gaboardi, Franco
Maatman, Thomas J.
Mottrie, Alexandre
Wijburg, Carl
Stöckle, Michael
Hemal, Ashok
Kim, Eric
Kaouk, Jihad
Hussein, Ahmed A.
Guru, Khurshid A.
Language: English
Title: The Journal of Urology
Volume: 203
Issue: 1
Pages: 57-61
Publisher/Platform: American Urological Association
Year of Publication: 2020
Free key words: urinary bladder
cystectomy
robotic surgical procedures
morbidity
mortality
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Purpose: We sought to determine the trend of neoadjuvant chemotherapy use for nonmetastatic muscle invasive urothelial bladder cancer and whether it is associated with adverse perioperative morbidity after robot-assisted radical cystectomy. Materials and Methods: We retrospectively reviewed the IRCC (International Robotic Cystectomy Consortium) database between 2006 and 2017. After excluding patients with nonmuscle invasive bladder cancer the patients were divided into 2 groups, including those who did vs did not receive neoadjuvant chemotherapy. Data were reviewed for demographics, preoperative, operative and 90-day perioperative outcomes. We used the Cochran-Armitage trend test to assess trends of neoadjuvant chemotherapy associations with high grade and overall complications with time. Multivariate stepwise regression analyses were done to determine whether neoadjuvant chemotherapy was associated with prolonged operative time, 90-day postoperative complications, readmissions, reoperations and mortality after robot-assisted radical cystectomy. Results: A total of 298 patients (26%) received neoadjuvant chemotherapy. These patients were younger (age 67 vs 69 years, p=0.01) and more frequently had an ASA™ (American Society of Anesthesiologists™) score of 3 or greater (62% vs 55%, p=0.02) and pathological T3 stage or greater disease (28% vs 22%, p=0.04). The use of neoadjuvant chemotherapy increased significantly from 10% in 2006 to 2007 to 42% in 2016 to 2017 (p <0.01). On multivariate analysis neoadjuvant chemotherapy was not significantly associated with prolonged operative time, hospital stay, 90-day postoperative complications, reoperation or mortality. Neoadjuvant chemotherapy was associated with 90-day readmissions after robot-assisted radical cystectomy (OR 5.90, 95% CI 3.30–10.90, p <0.01). Conclusions: Neoadjuvant chemotherapy utilization has significantly increased in the last decade. It was not associated with perioperative surgical morbidity after robot-assisted radical cystectomy.
DOI of the first publication: 10.1097/JU.0000000000000445
URL of the first publication: https://www.auajournals.org/doi/10.1097/JU.0000000000000445
Link to this record: urn:nbn:de:bsz:291--ds-377254
hdl:20.500.11880/34114
http://dx.doi.org/10.22028/D291-37725
ISSN: 1527-3792
0022-5347
Date of registration: 26-Oct-2022
Faculty: M - Medizinische Fakultät
Department: M - Urologie und Kinderurologie
Professorship: M - Prof. Dr. Michael Stöckle
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
There are no files associated with this item.


Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.